Back to trial detailsIntake questionnaire
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Applying to SCRI Oncology Partners - Tennessee · Nashville, Tennessee
Answer a few short questions to share with the research team.
0 of 4 answered